The Centers for Medicare and Medicaid Services (CMS) identified 15 drugs it has selected for price negotiations with drug ...

Former Trump administration health official Joe Grogan applauds Biden proposal that Medicare and Medicaid cover GLP-1 ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Saving more, paying down debt and building wealth are top financial goals for many Americans. CNBC's Senior Personal Finance Correspondent Sharon Epperson and Anchor Kelly Evans share advice on how to ...

Novo Nordisk A/S’s blockbuster drug Wegovy was targeted for price cuts by the US government and suffered a setback in a new ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost more weight than those on a lower dose without experiencing an increase in side-effects, according to a ...

Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug ...

Biden administration selects 15 new medications up for price negotiations including weight loss drugs Ozempic and Wegovy.

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Mounjaro, like other GLP-1 drugs, carries potential side effects, including nausea, vomiting, dehydration, and hypoglycaemia ...

Novo Nordisk's STEP UP trial shows semaglutide 7.2 mg delivers superior weight loss and safety compared to lower doses and ...